NCT03852264

Brief Summary

This study investigates the roles of oxytocin pathways in human-animal interaction.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
55

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 19, 2019

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 25, 2019

Completed
11 days until next milestone

Study Start

First participant enrolled

March 8, 2019

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 10, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 10, 2022

Completed
2.8 years until next milestone

Results Posted

Study results publicly available

November 12, 2024

Completed
Last Updated

November 12, 2024

Status Verified

March 1, 2024

Enrollment Period

2.8 years

First QC Date

February 19, 2019

Results QC Date

January 4, 2023

Last Update Submit

September 6, 2024

Conditions

Keywords

OxytocinCortisolHuman-animal interaction

Outcome Measures

Primary Outcomes (2)

  • Salivary Oxytocin, Area Under the Curve

    Change from baseline measured as the area under the curve with respect to the initial value (AUCi).

    baseline, 15 minutes

  • Urinary Oxytocin, Area Under the Curve

    Change from baseline measured as the area under the curve with respect to the initial value (AUCi).

    baseline, 50 minutes

Secondary Outcomes (2)

  • Salivary Cortisol, Area Under the Curve

    baseline, 50 minutes

  • Urinary Vasopressin, Area Under the Curve

    baseline, 50 minutes

Study Arms (2)

Pet Dog Interaction first, then Nonsocial Control, then Unfamiliar Dog Interaction

EXPERIMENTAL

Participant's first study visit involved 25 minutes of interaction with the participant's pet dog. The second study visit involved 25 minutes of individual play with toys. The third study visit involved 25 minutes of interaction with an unfamiliar dog.

Behavioral: Pet dogBehavioral: Unfamiliar dogBehavioral: Nonsocial control

Unfamiliar Dog Interaction first, then Nonsocial Control, then Pet Dog Interaction

EXPERIMENTAL

Participant's first study visit involved 25 minutes of interaction with an unfamiliar dog. The second study visit involved 25 minutes of individual play with toys. The third study visit involved 25 minutes of interaction with the participant's pet dog.

Behavioral: Pet dogBehavioral: Unfamiliar dogBehavioral: Nonsocial control

Interventions

Pet dogBEHAVIORAL

Children will interact freely with their pet dog for 25 minutes.

Pet Dog Interaction first, then Nonsocial Control, then Unfamiliar Dog InteractionUnfamiliar Dog Interaction first, then Nonsocial Control, then Pet Dog Interaction
Unfamiliar dogBEHAVIORAL

Children will interact freely with an unfamiliar dog for 25 minutes

Pet Dog Interaction first, then Nonsocial Control, then Unfamiliar Dog InteractionUnfamiliar Dog Interaction first, then Nonsocial Control, then Pet Dog Interaction

Children will play with age-appropriate toys/games for 25 minutes.

Pet Dog Interaction first, then Nonsocial Control, then Unfamiliar Dog InteractionUnfamiliar Dog Interaction first, then Nonsocial Control, then Pet Dog Interaction

Eligibility Criteria

Age8 Years - 10 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Participants in this study will include typically-developing children between 8-10 years who have lived with a companion dog in the household for at least 6 months.

You may not qualify if:

  • known medical diseases or injuries involving the central nervous or endocrine systems, major physical abnormalities, seizures, and significant sensory, cognitive, or motor impairments, current use of psychoactive medications

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Arizona

Tucson, Arizona, 85721, United States

Location

MeSH Terms

Conditions

Human-Animal BondHuman-Animal Interaction

Condition Hierarchy (Ancestors)

Behavior

Results Point of Contact

Title
Dr. Evan MacLean
Organization
University of Arizona

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Personnel analyzing hormones will be blinded to the experimental condition samples were collected from.
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Model Details: Within-subjects, 3 conditions, 2 condition orders balanced across participants
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 19, 2019

First Posted

February 25, 2019

Study Start

March 8, 2019

Primary Completion

January 10, 2022

Study Completion

January 10, 2022

Last Updated

November 12, 2024

Results First Posted

November 12, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations